Harvard Bioscience Inc. develops specialized life science research and preclinical equipment, targeting translational medicine through bridging in vivo and in vitro workflows. Despite broad global reach and a diverse customer base, the company reported a steep decline in profitability in 2025, with operating loss expanding to $48.6 million and net losses exceeding $56 million [F1]. The strategic plan centers on manufacturing consolidation to improve margins and a shift toward high-margin consumables and software to increase recurring revenues [S1,S26]. Key risks include execution of Project Viking restructuring, intense competition, and ongoing leverage from debt refinancings in late 2025 [S4-S13].